HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Core Viewpoint - HeartSciences Inc. is advancing its MyoVista Insights™ healthcare IT platform and has submitted its MyoVista® wavECG™ device for FDA clearance, aiming to modernize ECG through AI integration [1][6]. Financial Results - The company reported no meaningful revenue for the fiscal third quarter ended January 31, 2026, as it focuses on the commercialization of the MyoVista Insights platform [6]. - As of January 31, 2026, HeartSciences had approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders' equity [7]. Product Development - HeartSciences is advancing the commercialization of its MyoVista Insights platform and has submitted the MyoVista wavECG device to the FDA for 510(k) premarket clearance [2][4]. - The MyoVista Insights platform is classified as a Medical Device Data System (MDDS), which allows for a faster and less costly commercial rollout compared to regulated medical devices [5]. Management Commentary - The CEO highlighted strong progress towards 2026 objectives, including establishing reference sites and generating revenue for MyoVista Insights [5]. - The company has received compelling early feedback and is in discussions with multiple health systems regarding deployment [5]. Market Opportunity - MyoVista Insights is designed to enable the integration of AI-ECG algorithms into clinical practice, positioning HeartSciences to participate in a multi-billion-dollar AI-ECG market opportunity [5]. - The platform aims to host third-party algorithms alongside its own technologies, reducing costs and time for algorithm development and regulatory clearance [5]. Upcoming Events - Following the public introduction of MyoVista Insights at the ACC Annual Scientific Session, the company plans to host an investor call to demonstrate the platform and discuss its commercialization strategy [5].